ADCY4
-
Official Full Name
adenylate cyclase 4
-
Synonyms
ADCY4; adenylate cyclase 4; adenylate cyclase type 4; AC4; ADCY4_HUMAN; Adenylate cyclase type IV; Adenylyl cyclase 4; Adenylyl cyclase; ATP pyrophosphate lyase 4; ATP pyrophosphate lyase; ATP pyrophosphate-lyase 4; mKIAA4004;
Species | Cat.# | Product name | Source (Host) | Tag | Protein Length | Price |
---|---|---|---|---|---|---|
Mouse | Adcy4-6926M | Recombinant Mouse Adcy4 protein, His & T7-tagged | E.coli | His/T7 |
![]() |
|
Rat | Adcy4-3175R | Recombinant Rat Adcy4, GST-tagged | E.Coli or Yeast | GST |
![]() |
- Involved Pathway
- Protein Function
- Interacting Protein
- ADCY4 Related Signal Pathway
ADCY4 involved in several pathways and played different roles in them. We selected most pathways ADCY4 participated on our site, such as Purine metabolism, Rap signaling pathway, Calcium signaling pathway, which may be useful for your reference. Also, other proteins which involved in the same pathway with ADCY4 were listed below. Creative BioMart supplied nearly all the proteins listed, you can search them on our site.
Pathway Name | Pathway Related Protein |
---|---|
Purine metabolism | NT5C3A;ENTPD2A.1;AK5;ITPA;ALLC;POLR3E;HPRT1;ADKB;NT5C2B |
Rap signaling pathway | ANGPT2;ACTG1;MAGI1;PLCE1;FLT1;FGFR2;PDGFC;PARD6B;CALM4 |
Calcium signaling pathway | GNAL;PRKACAB;HTR5AL;ERBB4;LTB4R2;TACR2;F2R;CACNA1SB;DRD1A |
cGMP-PKG signaling pathway | NPR1;PRKG2;ATF4;AGTR1B;PPIF;PDE2A;RHOA;MAPK3;MYH7 |
cAMP signaling pathway | HTR1E;DRD1A;CALML5;PTGER3;GLP1R;GRIN3B;RAC3;CALM4;PPP1R12A |
Chemokine signaling pathway | STAT2;PLCB1;GNG2;CCR8;GSK3A;CXCL3;CXCR4;CDC42;ROCK2 |
Phospholipase D signaling pathway | GRM6;MAPK3;PDGFD;FCER1G;PDGFB;PDGFA;PLCB2;AGTR1A;AKT1 |
Oocyte meiosis | YWHAE;MAPK3;INS2;CALM1A;SKP1;MAPK12B;ANAPC11;CAMK2B;PPP3CCA |
Adrenergic signaling in cardiomyocytes | ACTC1B;GNAI2B;TPM4;TNNC1;ATP2B3B;MYL2B;ATP2A2;ATP2B2;PPP1CAA |
Vascular smooth muscle contraction | PPP1CBL;NPR2;CALM2A;PLA2G6;ARHGEF11;MYL6B;MLCK2;PLCB3;CALM3B |
Gap junction | PRKACBB;ITPR3;PLCB3;PDGFAB;MAPK1;TUBA3C;GNA15.4;TUBB;GJA1 |
Platelet activation | PTGS1;VAMP8;ROCK1;PRKG2;PIK3CD;MYLK4;MAPK11;SYK;PRKG1 |
Circadian entrainment | GUCY1B3;PLCB4;GRIN2D;GNB1;GNG13;GNG12;Adcy4;GNG5;PRKCG |
Retrograde endocannabinoid signaling | PRKACG;MAPK8;GNG12;GABRA4;GRIA2;PRKCA;GABRE;MAPK11;PRKCB |
Glutamatergic synapse | GNAI1;SLC17A8;PLCB1;HOMER2;ITPR3;GNB1;GRM8;GRIN3A;GRIN2A |
Cholinergic synapse | GNAO1;CAMK2B;CAMK2D;PRKCG;CHRNA4;GNG10;GNB3;CHRNB2;PRKCB |
GABAergic synapse | SLC38A2;GNG11;SLC12A5;GABRA2;GNG13;GLS2;GABRA3;GNB3;SLC38A5 |
Taste transduction | TAS2R124;TAS2R40;TAS2R125;GRM4;TAS2R126;KCNB1;TAS1R2;GNAT3;PLCB2 |
Inflammatory mediator regulation of TRP channels | CAMK2G;PIK3R1;IL1R1;PRKACA;IL1RAP;PPP1CA;MAPK9;HRH1;PRKCQ |
Insulin secretion | GNAS;PLCB4;PRKCG;CAMK2A;KCNMB1;VAMP2;ATP1B1;PRKCB;GLP1R |
GnRH signaling pathway | GNRH3;PLD1A;PRKACA;GNRHR1;FSHB;EGFRA;PRKCBA;MAPK12;PRKCDA |
Ovarian steroidogenesis | STAR;Adcy4;LHB;IGF1;PLA2G4A;HSD17B1;BMP15;GNAS;HSD3B2 |
Progesterone-mediated oocyte maturation | MAPK11;CPEB1;CCNA2;CDK1;INS1;CDC25C;CPEB2;PIK3CB;RPS6KA1 |
Estrogen signaling pathway | HSPA8;CALM4;CREB3L2;GNAI1;GNAI2;PLCB3;SHC2;ITPR1;KCNJ5 |
Melanogenesis | WNT11B;TCF7L1A;CALML3;WNT4A;KIT;FZD8A;DVL3A;PRKACG;GNAIA |
Thyroid hormone synthesis | ITPR3;GPX2;PRKCB;ATP1A3;FXYD2;GNAQ;PRKCG;GSR;PLCB1 |
Oxytocin signaling pathway | NFATC2;MAP2K5;PIK3R5;NFATC4;PPP1R12A;CD38;MAP2K2;RHOA;PRKACA |
Regulation of lipolysis in adipocytes | PIK3CG;GNAS;PRKACA;GNAI1;PIK3CD;PRKACG;PTGER3;IRS1;INS1 |
Aldosterone synthesis and secretion | CAMK2G;CAMK2B;PRKD1;CYP21A1;ADCY8;KCNK9;ADCY3;CALM1;PLCB1 |
Salivary secretion | AMY1A;STATH;PRH1;RYR3;Adcy4;PRKG2;ATP1A2;CALML3;ITPR1 |
Gastric acid secretion | CALM2;CALML5;EZR;PLCB4;SSTR2;SLC9A1;Adcy4;PLCB2;PRKACA |
Pancreatic secretion | Car2;CCKAR;FXYD2;CLCA1;ATP2B4;SLC9A1;ATP2A1;CLCA3;PLCB4 |
Bile secretion | ATP1B1;ABCC3;SLC22A1;KCNN2;SLCO1A4;ATP1A4;LDLR;ATP1A3;SULT2A1 |
HTLV-I infection | MSX1;IKBKG;Pdgfa&Pdgfb;XIAP;HLA-DQA1;APC2;HLA-DPB1;HLA-F;IL2RA |
Pathways in cancer | TGFBR2;FZD6;RAC1;GSTP1;PRKACA;LAMB3;ARHGEF1;RALB;BIRC5 |
Dilated cardiomyopathy | CACNB3;PRKACG;Adcy4;TGFB3;ITGA4;MYL3;TGFB1;MYH7;CACNB2 |
ADCY4 has several biochemical functions, for example, ATP binding, G-protein beta/gamma-subunit complex binding, adenylate cyclase activity. Some of the functions are cooperated with other proteins, some of the functions could acted by ADCY4 itself. We selected most functions ADCY4 had, and list some proteins which have the same functions with ADCY4. You can find most of the proteins on our site.
Function | Related Protein |
---|---|
ATP binding | DDR1;ACSL5;MYLK4;CHORDC1;MSH5;STK39;ABCG2D;ATP2B1;BCKDK |
G-protein beta/gamma-subunit complex binding | PIK3R5;Adcy4;GNAQ;GNA13A;GNA15.4;GNA11;GNAO1A;GNAS;CETN4 |
adenylate cyclase activity | Adcy4;ADCY7;ADCY8;ADCY1B;GNAS;ADCY1A;ADCY1;ADCY2B;ADCY9 |
metal ion binding | C2;ZFP326;CYP2C39;ZNF507;ATP13A;ARFGAP1;IKZF5;XPA;NUDT8 |
nucleotide binding | RBPMS;CSNK2A2A;ACTR2B;CIRBPA;ATP2B3B;MTIF2;APAF1;ARF6B;RBPMS2A |
ADCY4 has direct interactions with proteins and molecules. Those interactions were detected by several methods such as yeast two hybrid, co-IP, pull-down and so on. We selected proteins and molecules interacted with ADCY4 here. Most of them are supplied by our site. Hope this information will be useful for your research of ADCY4.
- Q&As
- Reviews
Q&As (13)
Ask a questionAdcy4 has the potential to be used as a biomarker for some types of cancer. Its overexpression has been linked to several types of cancer, including breast, colorectal, and lung cancer. However, further research is needed to determine its exact role as a biomarker, and more studies are needed to validate its utility as a diagnostic tool.
There is always the potential for side effects with any drug targeting Adcy4. However, since this protein is expressed in a variety of tissues and plays a role in many different biological processes, any drug targeting Adcy4 would need to be designed specifically to minimize off-target effects.
Yes, Adcy4 is a promising therapeutic target in hypertension. Experimental studies have shown that inhibiting Adcy4 activity can reduce blood pressure in animal models. Developing drugs that specifically target Adcy4 could provide a new and effective treatment option for hypertension.
Yes, Adcy4 has potential therapeutic targets in neurological disorders such as Alzheimer's and Parkinson's. Studies suggest that Adcy4 plays a role in modulating neuronal excitability and plasticity, and targeting Adcy4 could lead to the development of new drugs for these disorders.
Several techniques are used to study Adcy4 protein, including gene expression analysis, immunohistochemistry, Western blotting, and proteomic approaches such as mass spectrometry. In addition, animal models and cell culture systems are used to study the functional role of Adcy4 in various biological processes.
Yes, targeting Adcy4 with drugs could potentially have side effects, especially if the target is not selective. Adcy4 has a role in multiple cellular processes, and therefore it is crucial to carefully evaluate the potential drugs and their effects on other cellular processes to lessen unwanted side effects.
Drug development is a complex and time-consuming process that can take several years or even decades. It depends on many factors, including the availability of funding, the success of preclinical studies, and the safety and efficacy of the drug in clinical trials. However, because Adcy4 is a promising target for several different diseases, there is likely to be ongoing research in this area for years to come.
Adcy4 protein expression levels could potentially be used as a diagnostic marker for some diseases. For example, increased levels of Adcy4 have been associated with heart failure, and measuring Adcy4 expression may help with early diagnosis and patient monitoring.
Yes, Adcy4 research could lead to the development of new drugs that target cAMP signaling pathways in a more specific and effective way than currently available treatments. This could lead to improved outcomes for patients with diseases such as hypertension and heart failure.
Yes, personalized medicine approaches could potentially be developed based on Adcy4 expression levels. Measuring Adcy4 expression could help identify patients who are more likely to respond to certain treatments and stratify patients into specific subgroups for more targeted therapies.
Yes, Adcy4 is a promising target for developing new treatments for heart disease. The protein plays a role in regulating cardiac function and has been linked to heart failure and other cardiovascular diseases. Inhibiting Adcy4 activity could help to improve cardiac function and reduce the risk of heart failure.
Adcy4 protein has potential applications in medicine for the treatment of several diseases, such as hypertension, heart failure, and certain types of cancer. Understanding the role of Adcy4 in these diseases could lead to the development of new druggable targets and therapies.
Adcy4 protein is regulated by a variety of mechanisms in the body. Some regulators of Adcy4 expression include transcription factors, post-translational modifications such as phosphorylation, and various signaling pathways that can either activate or inhibit Adcy4 activity.
Ask a Question for All ADCY4 Products
Required fields are marked with *
My Review for All ADCY4 Products
Required fields are marked with *